前立腺肥大症に対するAllylestrenol(OrgAL-25)の臨床的検討--経直腸的超音波断層法による前立腺形態、重量の変化と排尿機能の変化について--

概要

論文の詳細を見る
前立腺肥大症17例に,allylestrenol 50 mg/日を長期投与(平均37.7週)したところ,1)自・他覚症状の改善が42.9%～92.9%の症例にみられた.2)経直腸的超音波断層法では,前立腺重量で有意な減少が認められ,前後径,左右径でも有意な縮小を認めたが,上下径では縮小傾向に留まった.3)膀胱内圧は64.3%に上昇を,尿道壁圧曲線下面積は54.5%に減少を認めた.4)血清中性脂肪,βおよびPre-βリポ蛋白値はほとんどの症例が正常域内の変動であった.5)血清ホルモン値では,テストステロンに著明な低下を認めた他は,特記すべき変化はみられなかった.6)副作用については,軽度***・ポテンツ低下が1例に認められたのみであった.7)以上の結果から本剤の有用性を確認したSeventeen patients with benign prostatic hypertrophy were treated with 50 mg allylestrenol per day for a long period of time (mean: 37.7 weeks), and subjective and objective findings, transrectal ultrasonotomography, urodynamics, serum lipids and hormone levels were examined. Improvement rates of subjective and objective findings were 42.9-92.9%. A significant decrease in weight and diameter (antero-posterior, lateral) of the prostate was observed, but the difference in the height of the prostate was not significant. Increase in intravesical pressure was observed in 9 out of 14 cases (64.3%) and the decrease in area under the urethral pressure curve at functional profile length was observed in 6 out of 11 cases (54.5%). Slight increase of the serum lipid levels was observed in a few cases, but in many cases the fluctuation was within normal range. Although clear decrease in the testosterone levels was seen, decrease of libido and potency was observed in only one case (5.9%). No other side-effect was found. The overall efficacy rate was 58.8%, and clinical usefulness of Allylestrenol on benign prostatic hypertrophy was confirmed.

前立腺肥大症に対するAllylestrenol(OrgAL-25)の臨床的検討--経直腸的超音波断層法による前立腺形態、重量の変化と排尿機能の変化について--

スポンサーリンク

概要

著者

関連論文

スポンサーリンク